Dataset Information
Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade.
Ontology highlight
ABSTRACT: Background
Immune checkpoint blockade can provide clinical benefit for patients with advanced cancer. Here, we report durable disease control over many years following PD-L1 blockade through induction of a viral antigen-specific T cell response in an adult patient with recurrent respiratory papillomatosis.Methods
Antigen-specific T cell response assays, single cell RNA-sequencing, and RNA-scope was used to study clinical tissues.Results
An HPV6 E2-specific T cell clone restricted to HLA-B*55, present at low frequency in the pre-treatment papilloma, significantly expanded after six doses of PD-L1 blockade and remained present and functional at the site of initial response in the larynx as a tissue resident memory T cell for 4 years. An associated reduction in E2 target gene was observed following treatment.Conclusions
Although demonstrated in a single exceptional responder, these results highlight that immune checkpoint blockade may induce durable, viral antigen-specific immunity of sufficient magnitude to control disease in patients with nonmalignant disorders.
SUBMITTER: Bai K
PROVIDER: S-EPMC9452466 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature
Publications
Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade.
Head & neck 20220711 10
<h4>Background</h4>Immune checkpoint blockade can provide clinical benefit for patients with advanced cancer. Here, we report durable disease control over many years following PD-L1 blockade through induction of a viral antigen-specific T cell response in an adult patient with recurrent respiratory papillomatosis.<h4>Methods</h4>Antigen-specific T cell response assays, single cell RNA-sequencing, and RNA-scope was used to study clinical tissues.<h4>Results</h4>An HPV6 E2-specific T cell clone re ...[more]
